Campbell, P.O.; Bauro, T.; Rimon, E.; Timeon, E.; Bland, C.; Ioteba, N.; Douglas, N.M.; Cunanan, A.; Chambers, S.T. Single-Dose Rifampicin Leprosy Chemoprophylaxis for Household Contacts in Kiribati: An Audit of a Combined Retrospective and Prospective Approach. Trop. Med. Infect. Dis.2024, 9, 58.
Campbell, P.O.; Bauro, T.; Rimon, E.; Timeon, E.; Bland, C.; Ioteba, N.; Douglas, N.M.; Cunanan, A.; Chambers, S.T. Single-Dose Rifampicin Leprosy Chemoprophylaxis for Household Contacts in Kiribati: An Audit of a Combined Retrospective and Prospective Approach. Trop. Med. Infect. Dis. 2024, 9, 58.
Campbell, P.O.; Bauro, T.; Rimon, E.; Timeon, E.; Bland, C.; Ioteba, N.; Douglas, N.M.; Cunanan, A.; Chambers, S.T. Single-Dose Rifampicin Leprosy Chemoprophylaxis for Household Contacts in Kiribati: An Audit of a Combined Retrospective and Prospective Approach. Trop. Med. Infect. Dis.2024, 9, 58.
Campbell, P.O.; Bauro, T.; Rimon, E.; Timeon, E.; Bland, C.; Ioteba, N.; Douglas, N.M.; Cunanan, A.; Chambers, S.T. Single-Dose Rifampicin Leprosy Chemoprophylaxis for Household Contacts in Kiribati: An Audit of a Combined Retrospective and Prospective Approach. Trop. Med. Infect. Dis. 2024, 9, 58.
Abstract
Kiribati is a Pacific Island nation with a widely dispersed population and one of the highest rates of leprosy worldwide. Single dose rifampicin post exposure prophylaxis (SDR-PEP) of leprosy contacts has reduced new case detection rates in controlled trials. In 2018, a SDR-PEP programme was introduced in Kiribati that included screening and chemoprophylaxis of household contacts of leprosy cases both retrospectively (2010-2017) and prospectively (2018 onwards). We conducted a retrospective audit to determine comprehensiveness, timeliness and feasibility of the SDR-PEP programme. Overall, 13,643 household contacts were identified (9,791 in the retrospective and 3,850 in the prospective cohort). In the retrospective cohort, 1,044 (11%) contacts were absent, 403 (4%) were ineligible for SDR and 42 new cases were detected (0.4%) Overall SDR coverage was 84.7%. In the prospective cohort, 164 (4%) contacts were absent, 251 (7%) were ineligible for SDR and 23 new cases were diagnosed (0.6%). Overall, SDR coverage was 88.1%. Across both cohorts, there were a total of 23 SDR refusals. The median time to SDR ad-ministration was 220 days (IQR 162-468) and 120 days (IQR 36-283) for the retrospective and prospective cohorts respectively. SDR was readily accepted in both cohorts. The new case detec-tion rate (0.5%) is consistent with that seen in other studies. Overall SDR coverage in both the retrospective and prospective phases met programmatic expectations.
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
